Edition:
India

SAGE Therapeutics Inc (SAGE.OQ)

SAGE.OQ on NASDAQ Stock Exchange Global Market

168.67USD
22 Jan 2018
Change (% chg)

-- (--)
Prev Close
$168.67
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
307,165
52-wk High
$180.50
52-wk Low
$44.58

Latest Key Developments (Source: Significant Developments)

Sage Therapeutics Reports Positive Results From Phase 2 Placebo-Controlled Trial Of Sage-217 In Major Depressive Disorder
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Sage Therapeutics Inc ::SAGE THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 PLACEBO-CONTROLLED TRIAL OF SAGE-217 IN MAJOR DEPRESSIVE DISORDER.SAGE THERAPEUTICS - SAGE-217 MET PRIMARY ENDPOINT AND PROVIDED RAPID, DURABLE EFFECTS THROUGH 2-WEEK TREATMENT PERIOD AND ADDITIONAL 4-WEEK FOLLOW-UP.SAGE THERAPEUTICS - PHASE 2 TRIAL OF SAGE-217​ ‍WELL-TOLERATED.SAGE THERAPEUTICS INC - DATA FROM PHASE 2 STUDY SUPPORT FURTHER DEVELOPMENT OF SAGE-217 FOR MDD AND RELATED DISORDERS.SAGE THERAPEUTICS - SAGE-217 DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT MEAN REDUCTION IN HAM-D SCORE COMPARED TO PLACEBO AT 15 DAYS​.SAGE THERAPEUTICS INC - SAGE-217 HAD NO SERIOUS OR SEVERE ADVERSE EVENTS IN PHASE 2 STUDY.SAGE THERAPEUTICS - ALL SECONDARY ENDPOINTS WERE CONSISTENT WITH PRIMARY ENDPOINTS AT DAY 15 OF TRIAL OF SAGE-217.  Full Article

Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Sage Therapeutics Inc -:SAGE THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE.  Full Article

Sage Therapeutics announces proposed public offering of common stock
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces proposed public offering of common stock.Sage Therapeutics Inc - ‍has commenced an underwritten public offering of $300.0 million of its common stock​.  Full Article

Sage Therapeutics announces Brexanolone achieves primary endpoints
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sage Therapeutics Inc ::Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression.Statistically significant mean reduction in HAM-D score compared to placebo at 60 hours demonstrated in both trials​.Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies​.Brexanolone achieved primary endpoint in both trials​.In each trial, 1 patient experienced serious adverse event; neither required hospitalization, 1 deemed not to be study-drug related​.Sage plans to file a New Drug Application (NDA) with U.S. Food and Drug Administration in 2018 for Brexanolone​.  Full Article

Sage Therapeutics announces qtrly loss per share $1.97‍​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Sage Therapeutics Inc :Sage Therapeutics announces third quarter 2017 financial results and provides pipeline update.Qtrly loss per share $1.97‍​.  Full Article

Sage Therapeutics advances SAGE-217
Monday, 13 Feb 2017 

Sage Therapeutics Inc - : Sage Therapeutics advances SAGE-217 into placebo-controlled phase 2 clinical trial in major depressive disorder . SAGE-217 was found to be generally well-tolerated with no serious adverse events or discontinuations reported .Statistically significant mean change from baseline was observed by day 2 of study.  Full Article

Sage Therapeutics starts Phase 2 clinical development for SAGE-217 in movement disorders
Tuesday, 13 Dec 2016 

Sage Therapeutics Inc : Essential tremor study is anticipated to report results in second half of 2017 . Sage Therapeutics announces initiation of Phase 2 clinical development for SAGE-217 in movement disorders . Sage Therapeutics - top-line results from part a open-label study in Parkinson's disease are expected in first half of 2017 .Also plans to initiate Phase 2 clinical trials of SAGE-217 in two mood disorders.  Full Article

Sage Therapeutics Q2 EPS ($1.08)
Tuesday, 9 Aug 2016 

Sage Therapeutics Inc : Sage Therapeutics announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $1.08.  Full Article

Sage Therapeutics says completed enrollment for Phase 2 trial of Sage-547
Friday, 27 May 2016 

Sage Therapeutics Inc :SAGE THERAPEUTICS announces completion of enrollment for phase 2 proof-of-concept trial of sage-547 in severe postpartum depression.  Full Article

Sage shares surge as depression drug succeeds in mid-stage trial

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.